{"links":{"html":"https://www.erudio.com/reports/sanovo-nct05009836","json":"https://www.erudio.com/reports/sanovo-nct05009836.json","markdown":"https://www.erudio.com/reports/sanovo-nct05009836.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"sanovo-05009836"}},"request":"https://www.erudio.com/contact?report=sanovo-05009836"},"offer":{"cited_commentary_sources":54,"verified_hcp_statements":78,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":13,"optional":true,"price_per_verified_person_usd":15,"price_usd":195,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"sanovo-nct05009836"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=sanovo-05009836","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/sanovo-nct05009836","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-27T10:28:11.592775Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":22,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":23,"title":"Primary endpoint: PFS"},{"claim_count":20,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":19,"title":"Secondary endpoints"},{"claim_count":27,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":24,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":15,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":12,"coverage":"discussed","id":"A1","source_count":11,"title":"Timing of MET targeting and alternative first-line regimens"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":8,"title":"MET assays, thresholds and practical patient identification"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":6,"title":"Broader applicability, patient communication and conditional regulatory implications"},{"claim_count":17,"coverage":"discussed","id":"A4","source_count":16,"title":"Congress prioritization and wider communication framing"},{"claim_count":16,"coverage":"discussed","id":"A5","source_count":13,"title":"Evidence maturity, statistical interpretation and readiness for practice"}],"counts":{"cited_sources":54,"claims_by_expression_type":{"comparison":5,"interpretation":15,"opinion":8,"primary_context":5,"question":5,"restatement":23,"uncertainty":3,"unspecified":14},"claims_by_kind":{"attributed_opinion":15,"limitation":1,"source_observation":62},"clinician_statements":23,"evidence_units":77,"findings":7,"people_cited":20,"people_identity_verified":13,"people_total":20,"screened_sources":100,"verified_claims":78},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":3,"experience":0,"questions":2,"restated":0,"views":9},"has_counterview":true,"limitations":2,"links":{"context":0,"support":16},"ma_question":true,"named_voices":10,"passages":12,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"Enthusiasm for upfront dual inhibition is not an unconditional endorsement of a new standard"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":1,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":8,"passages":9,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Baseline MET testing raises both a treatment-selection question and a patient-identification burden"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":2,"views":3},"has_counterview":true,"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":8,"passages":9,"sources":9,"sources_by_kind":{"commentary":9}},"title":"Tolerability may determine the value of first-line intensification"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":0,"views":4},"has_counterview":false,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":8,"passages":8,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"When to target MET, and against which alternative, remains an open clinical question"},{"id":"F5","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":14,"views":6},"has_counterview":true,"limitations":2,"links":{"context":1,"support":24},"ma_question":true,"named_voices":17,"passages":21,"sources":20,"sources_by_kind":{"commentary":18,"media":2}},"title":"Strong survival language needs to remain separate from statistical certainty and endpoint identity"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":7,"passages":7,"sources":7,"sources_by_kind":{"commentary":7}},"title":"China-specific evidence prompts questions about broader applicability and conditional access"},{"id":"F7","structure":{"claims":26,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":15,"views":11},"has_counterview":false,"limitations":2,"links":{"context":6,"support":33},"ma_question":true,"named_voices":20,"passages":26,"sources":24,"sources_by_kind":{"commentary":24}},"title":"Congress prioritization signals interest, while wider amplification carries different meanings"}],"medical_affairs_question":"Which baseline MET definition and benefit–toxicity evidence would justify upfront dual blockade rather than another first-line strategy or deferred MET targeting?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Enthusiasm concerns a selected upfront strategy, not an unconditional new standard"},{"id":"section-2","level":2,"title":"MET testing is a decision pathway, not merely an additional laboratory result"},{"id":"section-3","level":2,"title":"Safety language differs, and discontinuation matters to the interpretation"},{"id":"section-4","level":2,"title":"Upfront treatment has not settled the sequencing or alternative-regimen question"},{"id":"section-5","level":2,"title":"Survival enthusiasm needs endpoint, timing and source qualifications"},{"id":"section-6","level":2,"title":"Geographic applicability and possible access are conditional, distinct issues"},{"id":"section-7","level":2,"title":"Congress attention and wider amplification should not be counted as treatment endorsement"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":12},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":9}],"id":"T1","label":"Primary endpoint: PFS"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":17},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":6},{"id":"F6","shared_claims":4},{"id":"F7","shared_claims":7}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":6},{"id":"F5","shared_claims":7},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-27T10:28:11.592775Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-27T11:53:23Z","record_hash":"3aaf0baad23835b9d6d595057dfc8d12de1048621a637995dd726bac87eeec20","release_hash":"e06e29d94836f077dbec21a44a6fdb596a27fbf4353eb5a447b895e99ca4a983","report_id":"erudio-nct05009836","run_id":"ab98e71b-071b-43f4-ba64-57a36677461b","schema_version":"5.0","slug":"sanovo-05009836","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"SANOVO asks whether adding savolitinib to first-line osimertinib delays progression in advanced EGFR-mutated, MET-overexpressing NSCLC compared with osimertinib alone. Clinicians in the sources reviewed for this edition differ over readiness for a new standard. They express enthusiasm for upfront dual inhibition while scrutinizing tolerability and survival interpretation. Treatment timing and broader applicability remain open questions in their commentary. SANOVO’s main results are scheduled for ESMO 2026; this reflects commentary before that presentation.","meta_description":"100 sources screened · 78 verified statements (23 from speakers with a confirmed clinical role) from 54 sources · 7 findings. Updated Oct 27, 2026.","person_names_policy":"role_only","sample_findings":[]},"publication":{"approved_at":"2026-10-27T11:53:23Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":100},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion; repeated posts and reposts are not independent clinical opinions.","Some potentially relevant passages were not fully assessed. Unnamed references and differently worded trial references may be missing.","No trial protocol, exact-trial results publication or matching product-label documents were available, limiting independent assessment of methods, results and regulatory status.","Several numerical findings are second-hand accounts of conference talks. Their reporting does not establish details that the account itself omits.","PFS HRs differ between commentators, and the reviewed material does not explain those differences.","The reviewed statements do not provide a complete safety analysis or establish statistical significance for OS.","The clinical roles of Alex Ehsan, Adam Januszewski and Minhua Chu are not established in the sources reviewed. The interview identifies Qing Zhou, but independent identity confirmation is unavailable. Several other comments are from unnamed speakers whose identities and clinical roles are unknown.","The report spans different evidence stages. Earlier requests for full data should not be read as later reactions, and post dates do not prove session dates or changes of mind."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":51,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":54},"count":54,"evidence_window":{"end":"2026-10-26","start":"2021-09-08"},"retrieval_snapshot":"2026-10-27T00:54:54.270241Z","timeline":[{"count":1,"week":"2021-W36"},{"count":1,"week":"2022-W33"},{"count":1,"week":"2025-W34"},{"count":14,"week":"2026-W36"},{"count":1,"week":"2026-W38"},{"count":4,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":3,"week":"2026-W42"},{"count":4,"week":"2026-W43"},{"count":23,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05009836:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05009836:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2x6vd5f7bljet5g4vdmnrj7e-3mudnft3h3k2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-43fdk46qa5gsokzygzildsaq-3lws4pi4vxd2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3muf6imfoks2f","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3lws4oef4fg2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3myrfg4plvy2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-lujbajkmqw3sved26po3sdk7-3mugt2agjdn27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3lwwywx4d722e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ry3wmi3k2ygwgfstao5tw6wg-3muejmc7n5o22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ry3wmi3k2ygwgfstao5tw6wg-3mwo3se3xe526","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d47d41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435551115668385792:39ab517f-0bb8-488a-93e2-6a49cf67529e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435551238746148867:301a228f-6f6c-4d92-ae81-c72960cf489a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435551584893669383:b5a7c2cd-4dac-4c38-9af1-01628debb183","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435551785322786819:7f7f366d-c618-4990-ba30-1aa59855dade","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435552260289748995:342d6ad7-d213-47ae-97be-e9d27bca4349","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435560113763336201:c10d6bd1-99ec-4dc4-8e1a-f095f0fb7b03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435585045142458368:e8904640-a5a4-48d4-a91f-612abe642517","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435596054305587201:088597a5-e289-44be-895d-2f44bc8572ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435731592677363714:b0ecc633-2ab6-4f52-a559-0c492f0a3414","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435731615913811973:3a311ee9-1555-49a4-8671-f433c646e4a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435868349376843780:47dea3e7-680e-411b-95fc-d4202295989f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435941081141686272:ab3c9716-73f2-4e7f-b41e-c69a2b46e31c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435943005626716160:e107a6a6-7221-4672-aacc-cf2422836914","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435943051306930177:10004486-b138-4da7-9f70-90c7ec51a123","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1562517110282416133:bb52539d-5d6e-4669-8b0b-110de24c14c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701049943199486171:3d52c3e3-c540-42a0-8c56-d3c061b9b0b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715630501598318998:69ccc4ad-5c77-494a-978f-f5c1b85912ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715654562747703509:3724d823-ebfd-4f5d-88d1-f67f17ccc094","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957955821956132956:0c17debc-a0f3-479d-ab43-0123f8175a5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957955881141956808:74677dc0-eb2a-4c35-b664-fcb4716710de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957955937836154935:55a96b55-18c9-4381-8925-32fdcc07d91c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957956252471861494:b2023bda-0a99-47e2-8bc6-1bb0ebf7a2a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957956453605814301:6e070a3a-d34f-41fc-bb82-94a3d6104dad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957957673145569760:87c14a28-2c07-4f34-9599-98dd01b0ba5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957961552390418825:a896c17b-a152-4e7f-be98-5c43dc63282f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957991232694809033:c9ecf7ac-6b11-43b6-8366-0e82cb7b7249","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958057985302827137:51ba166f-88ae-4e45-9234-0985a3c4711d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958099183484764249:7c693265-efad-4063-85ee-e4fbd5f74e47","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958154892775669771:05d5fce3-f48e-4164-b4cf-9a607d6b13d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024889353537978591:6d9d1e2e-0e1c-4be1-b589-add4251de3e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094241333162713545:44b87ccf-7623-4f4b-a1af-d04e06b4b15b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094322497311158738:9e03903d-1725-4048-8a74-dec2b788c436","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094342707913077127:0589f8df-5294-4c09-a969-06ed19a72d24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094343644790575528:507d922e-3d43-46ec-91c2-d147f783eddb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094399519337095530:57794f7a-0ef3-467f-aca1-e988338ef9df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094702566890504382:0cf07789-d5e6-4460-a172-50418fb8f45d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094721573303316679:cefa540e-91c9-4c9e-8e34-4b87f067d9d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094733180712488965:7fd112cc-8c7c-41d3-84dc-cecf3e5ff5b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094738788744610221:33014358-d14b-4637-927d-2b6587def252","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094957502957822290:cb718763-63d5-4f07-b880-2cb8cd268c12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095149876225196287:c24a6c28-12f2-454e-91b5-a20e53a872a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095340186414743699:81b7b310-335f-4f74-b4f5-767fe02ffd93","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095551558385795494:2ce53c41-4246-4863-a12f-159abbb32ccf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100525183878504584:fe1c51bb-488e-4018-8403-40d2b93ea200","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102774996921913699:ce822e53-fbc6-4e5f-99c1-c1cd536d56d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102912773537624466:4fe4c914-2a65-4d78-8c69-d96cde6505ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103006179987517859:7876a876-fa47-47f6-b461-67f29a1c886e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103151255606726690:affcbae9-e263-4a8c-8c2e-bfb7af8a9b7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104926770810048757:46ba3039-a7c8-469d-bf76-7aaf4c3720c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104948255259836878:4c7b1529-0517-45d0-bff6-04ce3075c4ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105739913681416293:a528d67f-614a-4d55-91b2-f4a541c7473b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107390688413339706:b17c3c31-43b8-41ec-b2a8-c07f203d5227","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110661864174584072:593b662b-9e10-4764-b684-fade0d515c74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110663211145982161:dfc92712-9876-45d2-bea2-e969986e636c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110663501437895134:4f1c3460-8348-4179-805c-0b1e6f14e7e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112846605963407601:22191f05-21cf-49fe-ae37-f614a13b6570","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112867869759537359:41c5ee38-f46c-4e70-8695-11399f7c20ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113525926671605768:cb88ee34-0946-47a7-9ece-62fe27e06e19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113561393152540999:e27bd256-e61e-4763-849e-50910935d1ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114038371689365546:74291d35-5caf-458f-ab12-0bd923fcba9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114370585606410361:35a97b47-6b96-493e-b9bf-1eb04fd85976","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114474915868860510:a0e901d2-67a3-49c8-9b38-dac7c93569c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114510878477287429:9598b1fc-3775-4bb3-b811-377813daf38d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114606208355303771:a18c5dfd-ffc7-42b8-958b-bd25adbde9ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114623253314777270:6ecd3332-43ff-4c5a-a93b-57e73bfb1369","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114623689698517399:b33b484e-d7c3-4d17-b519-2837676aa741","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114623767540568372:1d7c1b8b-39d5-4085-83f5-36604c4e6385","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114623802453995627:c6fd66e7-6c49-48c3-b4ce-e5a85c3a537d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114624354055012376:19140057-ffde-494d-a9f1-8fa3cc7904ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114624847883948126:5ff2aec8-3f7b-49ec-83f9-82924043e34b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114630409518711132:efc77feb-b050-49b1-91c1-cfb67653fd06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114631656535400621:99a5586a-6e8b-451e-a8af-49ba6be53e13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114631847355318772:0f11eb56-957b-442a-b720-a1a9b8e78269","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114636231711879575:7c273241-a503-43ad-9f61-5a7175dab39e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114636345528254788:4403b234-627f-47af-8f65-9c1167c0afdc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637233584001300:e91f67eb-3810-42f5-8a53-3e402cde9c6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114672582935105667:f3b1f846-e953-42a4-a3ff-68131ca5a76e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114693995574235399:a2b7af85-c7c0-47a0-aeca-6aeae0ff0e82","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114694600636113190:fc76e0a9-7faa-44bf-9bbb-171dc4e70981","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114694834023739779:fb889240-66ed-4e38-a592-4aa7ef5a11e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114703874732990905:dc9e69b4-6e34-4ac0-83b5-2af11f8f7a72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114711310571094293:7ed81738-fffa-41fd-afb7-8d0ca617e56e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114719629163815254:e69720a3-f856-481a-a494-23a3d4fad61e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114746335999975781:51906f63-4fcd-4369-b003-c0f8d7394e8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114758111273869764:6584d004-bdc5-4268-8632-b450c95a3fb2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114759164287386047:c84d7017-86fb-4f4b-bd7a-6ab768db0488","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114836131946590705:731a55dc-81c6-4dae-9842-4b5ae29a03ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114842778471420333:c4b56cd8-8e73-4195-9a3d-c82668806913","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:8PiAglC621E","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:db7RaBF1byg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":9,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":88,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":100},"count":100,"evidence_window":{"end":"2026-10-26","start":"2021-09-08"},"retrieval_snapshot":"2026-10-27T01:10:36.492531Z","timeline":[{"count":14,"week":"2021-W36"},{"count":1,"week":"2022-W33"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2023-W37"},{"count":2,"week":"2023-W42"},{"count":14,"week":"2025-W34"},{"count":1,"week":"2026-W08"},{"count":17,"week":"2026-W36"},{"count":1,"week":"2026-W38"},{"count":5,"week":"2026-W39"},{"count":4,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":3,"week":"2026-W42"},{"count":8,"week":"2026-W43"},{"count":27,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: savolitinib","status":"unmapped"},{"brand_names":["Tagrisso"],"label":"osimertinib","slug":"osimertinib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SANOVO","aliases":["SANOVO","Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC"],"brief_title":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":412,"type":"ESTIMATED"},"interventions":[{"name":"Savolitinib","synonyms":["HMPL-504"],"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Osimertinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05009836","official_title":"A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-05-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)","measure":"PFS","timeFrame":"17 months after the last patient enrolled"}],"registry_last_updated":"2026-09-22","registry_url":"https://clinicaltrials.gov/study/NCT05009836","short_name":"SANOVO","short_name_basis":"registry_acronym","sponsor":"Hutchmed","start_date":{"date":"2021-09-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"2020-504-00CH4","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}